Cyclazocine revisited

Neurochemical Research

Volumn 21, Issue 11, 1996, Pages 1369-1373

  Archer, Sydney ^a   Glick, Stanley D ^b   Bidlack, Jean M ^c  

^a Research Rensselaer Polytechnic Institute   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Cyclazocine, mu antagonist; kappa agonist

Indexed keywords

COCAINE; CYCLAZOCINE; KAPPA OPIATE RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; OPIATE AGONIST; OPIATE ANTAGONIST;

ARTICLE; DRUG DEPENDENCE; DRUG SELF ADMINISTRATION; DRUG TOLERANCE; DYSPHORIA; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; WITHDRAWAL SYNDROME;

ANIMALIA;

EID: 0029957394     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02532378     Document Type: Article

References (22)

1. Kuhar, M. J. 1993. Neurotransmitter transporters as drug targets: recent research with a focus on the dopamine transporter. Pharmacologist, 35:28-33.
2. Devine, D. P., Leone, P., Pockok, D., and Wise, R. A. 1993. Differential involvement of ventral tegmental mu. delta and kappa receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies. J. Pharmacol. Exp. Ther. 266:1236-1246.
3. Spanagel, R., Herz, A., and Shippenberg, T. S. 1992. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc. Natl. Acad. Sci. USA 89: 2046-2050.
4. 2BAMO). J. Pharmacol. Exp. Ther. 262, 526-531.
5. Archer, S., Seyed-Mozaffari, A., Jiang, Q., and Bidlack, J. M. 1994. 14α4-14β [Dithiobis(2-oxo-2, 1-ethanediyl)imino]]bis-7,8-dihydromorphinone and 14α-14β-[dithiobis-92-oxo-2,1-ethanediyl)imino]]bis-7,8,-dihydro- (cyclopropylmethyl)-normorphinone. Chemistry and opioid binding properties. J. Med. Chem. 37, 1578-1585.
6. 1 antagonist. Bioorg. Med. Chem. Letters, 6:1139-1144.
7. Aceto, M. D., Bowman, E. R., Harris, L. S., Woods, J. H., Smith, C. B., Medzihradsky, F., and Jacobson, A. E. 1989. Very long-acting antagonists: the 14β-p-substituted cinnamoylmorphinones and their partial agonist codeinone relatives. Arzneim. Forsch. 39, 570-575.
8. Kosten, T. R., Kleber, H. D., and Morgan, L. 1989. Role of opioid antagonists in treating intravenous cocaine abuse. Life, Sci., 44: 141-148.
9. Mello, N. K., Mendelson, J. K., Bree, M. P., and Lukas, S. E. Buprenorphine suppresses cocaine self-administration by rhesus monkeys. Science, 248, 859-862.
10. Dichiara, G., and Imperato A., 1988. Opposite effects of mu and kappa agonists in dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J. Pharmacol. Exp. Ther. 244, 1067-1080.
11. Spealman, R. D., and Bergman, J., 1992. Modulation of the discriminative stimulus effects of cocaine by mu and kappa opioids. J. Pharmacol. Exp. Ther., 281, 607-615.
12. Maisonneuve, I. M., Archer, S., and Glick, S. D., 1994. A kappa opioid receptor agonist attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci. Lett. 181, 57-50.
13. Glick, S. D., Maisonneuve, I. M., Raucci, J., and Archer, S., 1994. Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Res. 681, 147-152.
14. Zernig, G., Winger, G. D., Issaevitch, T., Lewis, J. W., and Woods, J. H., 1995. Clocinnamox effects on intravenous self-administration of mu opioid agonists and cocaine by rhesus monkeys: agonist efficacy estimates. Abstr., CPDD Meeting, Scottsdale AZ, 160.
15. Archer, S. 1962. Brit. Pat. 611,000.
16. Harris, L. S., and Pierson, A. K., 1964. Some narcotic antagonists in the benzomorphan series. J. Pharmacol. Exp. Ther., 143, 141-148.
17. Archer, S., Pierson, A. K., Pittman, K., and Aceto, M. 1972. Pharmacological basis of pentazocine, pages 282-285, in Janzen, R., Keidel, W. D., Herz, A. S., Streichle, C., (eds.) Pain, George Theime, Publishers. Stuttgart.
18. De Kornfeld, T. J., and Lasgna, L. 1962. Win 20740, a potent new analgesic. Fed. Proc. 22:248.
19. Martin, W. R., Fraser, H. F., Gorodetsky, C. W., and Rosenberg, D. E., 1965. Studies of the dependence-producing potential of the narcotic antagonist 2-cyclopropylmethyl 2′-hydroxy-5,9-dimethyl-6,7-benzomorphan (cyclazocine), Win 20740, ARC II-3) J. Pharmacol. Exp. Ther. 150:426-436.
20. Martin, W. R., Gorodetzky, and McClane, T. K., 1966. An experimental study in the treatment of narcotic addicts with cyclazocine. Clin. Pharmacol. and Ther. 455-464.
21. Fink, M., Freedman, A. M., Esnick, R., and Zaks, A., 1972. Clinical status if the narcotic antagonists in opioid dependence. Agonist and antagonist actions of narcotic analgesic drugs, pages 266-276, In Kosterlitz, H. W., Collier, H. O. J., and Villareal, J. E., (eds.) Macmillan Press.
22. Resnick, R., Fink, M., and Freedman, A. M. 1971. Cyclazocine treatment of opiate dependence: a progress report. Compr. Psychiat. 12:496-501.